CASH COW

[Austin6310]

SQMN,chart is below news

City of Hope to Use Sequenom's MassARRAY(R) System and Portfolio of Application Tools for Cancer Research
Sequenom, Inc. logo. (PRNewsFoto)

SAN DIEGO, CA USA 05/23/2005


SAN DIEGO, July 19 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq:
SQNM) announced today that City of Hope National Medical Center (City of
Hope) has purchased Sequenom's MassARRAY genetic analysis system and
portfolio of application tools for the Center's molecular marker research
and individualized cancer care initiatives.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO )
"We will utilize Sequenom's platform and applications for quantitative
gene expression and methylation (epigenetic) studies. In addition, we will
use the high throughput genotyping application as an integral part of our
on-going research both to identify individuals at high risk for developing
cancer, and to aid in the development of therapeutic modalities based on
the unique genetic profile of a given patient," said Garry Larson, Ph.D.,
Associate Research Scientist, City of Hope. "The MassARRAY platform is
unique and particularly well-suited to our needs because it enables us to
perform many different types of analysis in a cost-effective manner and on
a single platform."
"The National Cancer Institute has designated City of Hope a
'Comprehensive Cancer Center,' one of just a handful of such elite
institutions nationwide, and we are excited that their researchers will use
the MassARRAY platform for their pioneering cancer studies involving
epigenetics," said Harry Stylli, Ph.D., President and Chief Executive
Officer of Sequenom. "Epigenetic analysis has significant clinical
potential in cancer research and other fields. Our MassARRAY technology
enables this important analysis and will help accelerate advancements in
understanding and potentially treating cancer and other diseases."
Other prominent cancer research institutions that have selected
Sequenom's MassARRAY technology platform include M.D. Anderson's Kleberg
Center and the Roswell Park Cancer Institute.
About City of Hope National Medical Center
Founded in 1913 and located northeast of Los Angeles in Duarte,
California, City of Hope is an innovative biomedical research, treatment,
and educational institution dedicated to the prevention and cure of cancer
and other life-threatening diseases. City of Hope is guided by a
compassionate patient-centered philosophy and is supported by a national
foundation of humanitarian philanthropy. Through a combination of
patient-centered care, state-of-the-art treatment and groundbreaking
research, City of Hope is a world-renowned leader in the fight against
cancer, diabetes, HIV/AIDS, and other devastating diseases.
About Sequenom
Sequenom is committed to providing the best genetic analysis products
that translate genomic science into superior solutions for non-invasive
prenatal testing, biomedical research, molecular medicine and agricultural
applications. The Company's proprietary MassARRAY system is a
high-performance DNA analysis platform that efficiently and precisely
measures the amount of genetic target material and variations therein. The
system is able to deliver reliable and specific data from complex
biological samples and from genetic target material that is only available
in trace amounts. The Company has exclusively licensed intellectual
property rights for the development and commercialization of non-invasive
prenatal genetic tests for use with the MassARRAY system and other
platforms.
Sequenom(R) and MassARRAY(R) are trademarks of Sequenom, Inc.
Except for the historical information contained herein, the matters set
forth in this press release, including statements regarding the City of
Hope National Cancer Center's expected use of the MassARRAY platform and
applications, the clinical potential of epigenetic analysis, and
acceleration of advancements in understanding and potentially treating
cancer and other diseases, are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are subject
to risks and uncertainties that may cause actual results to differ
materially, including the risks detailed from time to time in Sequenom's
SEC filings, including Sequenom's Annual Report on Form 10-K for the year
ended December 31, 2005, and its most recently filed quarterly report on
Form 10-Q and subsequent filings. These forward-looking statements are
based on current information that is likely to change. You are cautioned
not to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. All forward-looking
statements are qualified in their entirety by this cautionary statement,
and Sequenom undertakes no obligation to revise or update any
forward-looking statement to reflect events or circumstances after the
issuance of this press release.


SOURCE Sequenom, Inc.

Related links:
# http://www.sequenom.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, [e-mail]
# http://www.prnewswire.com/comp/124192.html /
Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2006 PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.